Corvus Pharmaceuticals: Insider Buying Ahead Of Potential Turnaround In Second Half Of 2019 [Seeking Alpha]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Seeking Alpha
Corvus Pharmaceuticals: Insider Buying Ahead Of Potential Turnaround In Second Half Of 2019 Summary Shares have lost over a third of their value since my initial article. I provide a recap of the bullish thesis and CEO Richard Miller's presentation at Jefferies Healthcare Conference. Insider buying by a couple directors and OrbiMed Advisors is encouraging. Much of management lineup is the same team that helped discover and develop ibrutinib at Pharmacyclics. Company has a solid cash position and several near to medium-term catalysts. I still believe that ITK inhibitor CPI-818 could make waves at ASH or in early 2020 with initial data. I suggest purchase of pilot position and accumulating dips. Shares of Corvus Pharmaceuticals ( CRVS Recently, the stock has seen some insider buying, including multiple purchases by OrbiMed Advisors ABBV Chart daily advanced chart (Source: Finviz) When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewswire
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $3.50 price target on the stock.MarketBeat
- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
CRVS
Earnings
- 11/7/23 - Beat
CRVS
Sec Filings
- 3/19/24 - Form 10-K
- 3/19/24 - Form 8-K
- 3/1/24 - Form 4
- CRVS's page on the SEC website